Introduction
============

Globally 106 countries from tropical and subtropical are endemic for malaria ([@B57]). These are in tropical or subtropical zones with are suitable breading places far anopheline mosquito. The regions included in this area are Asia, Africa, Islands of South, West and Central Pacific Ocean, Latin America, Turkey and certain Caribbean Islands ([@B21]). In the areas of malaria transmission, epidemics of malaria have been leading cause of high morbidity and mortality. Complex epidemics of malaria have been observed in Kenya (May 1999--August 1999, Burundi (September 2000--May 2001), South Sudan (June 2003--November 2003), in two areas of Ethiopia (July 2003--February 2004) and India (January 2005--March 2005) ([@B5], [@B20]).

In 3^rd^ world countries including Pakistan, malaria has always been major public health problem and it accounts for more than 95% of regional burden ([@B15]). The main reason of malariogenic potential in Pakistan is extensive agricultural practices, vast irrigation network, monsoon rains and poverty ([@B56]). Annually, about 500000 episodes of malaria infection occur ([@B58]) in rural areas, were associated with more people live below poverty line (38.65%) than urban areas (22.39%).

The main-stay in the control of malaria is the increasing frequency of drug resistant parasites especially *P. falciparum* ([@B11]).

First reports of resistance against CQ came from South America ([@B29]), South East Asia (Harinausta et al. 1965). Later, it reached to Africa. Across the world, CQR strain of *P. falciparum* originated from at least six locations independently: in Java, Philippines, Papua New Guinea, South East Asia and two locations in South America ([@B55], [@B6]). In Pakistan, the resistance of *P. falciparum* to CQ was first detected in 1981 from Sheikhupura and National Institute of Malaria Research and Training (NIMRT) revealed that R1 level of CQ resistance was widespread in Pakistan (frequency ranging from 30--84%) ([@B45]). Chloroquine was used as a first line treatment in Pakistan from 1950--2007 ([@B2]). In the district Muzaffargarh, response of *P. falciparum* to chloroquine was found out during the time period of 2003--2005. RI was 29.36 %, and RII was 29.41 % ([@B42]).

In 1990s, chloroquine resistant *P. falciparum* spread widely in Pakistan ([@B41]). Factors involved in the spread of drug resistance are drug use practices, drug half life, transmission intensity, clone multiplicity, parasite density, host immunity and genetic basis of drug resistance ([@B14], [@B38]). Resistance against many antimalarials has arisen in the same geographic areas. These areas have low transmission rate, low immunity level and higher parasites biomass ([@B54]). Use of substandard medicines can also be involved in the emergence of drug resistance ([@B23]).

With the advancement in molecular biology and isolation of CQ resistance clone (Dd2) helped in identification of molecular markers in *P. falciparum* associated with drug resistance (Jiang et al. 2008). In 1990, Thomas Wellem along with his team performed a cross between HB3, a chloroquine sensitive (CQS) and Dd2, a chloroquine resistant (CQR) strain ([@B52]). It was found that the main determinant of CQ resistance is a locus on chromosome 7 of *P. falciparum* ([@B53]). It was further noted that it is a 38 Kb fragment (10 genes) ([@B47]). Fidock et al. (2000) reported that a highly polymorphic 3.1 Kb gene (composed of 13 exons) is involved in resistance. [@B26] reported that it is a 48.6 kDa protein of 424 amino acids long. It forms 10 transmembrane domains. The protein is located on digestive vacuole and it has transporter-like properties. It was called *P. falciparum* chloroquine resistant transport gene (*pfcrt*) and considered as a member of drug metabolite transporter super family ([@B48]). In the past, SVMNT (ser-val-meth-asn-thr) allele carrying parasites had been reported twice, in 1996--1997 from Africa and in 2004 from Tanzania ([@B1]). Three common haplotypes of *pfcrt* are CVMNK (CQS, present in all geographic regions), CVIET (CQR found in Africa and South East Asia), SVMNT (CQR, S~agt~VMNT is present in some countries of Asia and S~tct~ VMNT is found in South America) ([@B55], [@B49]). The high level of resistance to AQ metabolite desethylamodiaquine (DEAQ) is found to be associated with the presence of *pfcrt* codon 72--76 haplotype SVMNT. It replaces CVMNK found in CQS strain ([@B55], [@B51], [@B43], [@B4]). In oocyte system, competition of drugs with CQ was checked by mutated *pfcrt*. Drug quinine and AQ at normal concentration and mefloquine and primaquine at higher concentration were able to compete with CQ for transport by mutated *pfcrt* while piperaquine and artemisinin did not interact with *pfcrt* ([@B27]).

Keeping in view the situation of malaria, this study was designed to identify the chloroquine resistant genes of *P. falciparum* which convert a chloroquine sensitive parasite (CQS) to chloroquine resistant (CQR) type parasite.

Materials and Methods
=====================

Selection of Area for Sampling
------------------------------

Muzaffargarh is located at latitude 30.06° longitudes 71.02°, between the two rivers, Chenab in the East and Indus in the West. For present study, the area of Muzaffargarh was selected on the basis of high endemicity. Data obtained by the curtsy of Directorate General Health Punjab, Pakistan (through personal communication) reported "1388 laboratory confirmed cases" in Punjab were with 15 % in district Muzaffargarh in 2006. In 2007, total number of positive malarial cases was 1903, again highest positive cases (7.5%) were observed in Muzaffargarh.

Sample Collection
-----------------

Blood samples were collected from individuals presented with fever, persistent headache and malaria like symptoms. Patient's consent was obtained prior to sampling, finger prick blood was used for slide preparation. Thick and thin blood smears were prepared and stained by Giemsa stain (3% solution in 7.2 pH phosphate buffer) (WHO 1991). Two ml blood of *P. falciparum* positive patients was collected in EDTA vacutainers and spotted on Flinders Technical Associates (FTA) classic cards (Whatman) by micropipette according to manufacturer's instruction. Vacutainers were stored at 4 °C and cards were stored at room temperature till use for DNA extraction. Sampling was done at Rural Health Centers Muzaffargarh from November, 2008 to November, 2010 (25 months) as shown in [Fig. 1](#F1){ref-type="fig"}.

![Map of district Muzaffargarh showing RHCs](JAD-9-204-g001){#F1}

DNA Extraction
--------------

For amplification of *pfcrt* gene, DNA was eluted both from FTA cards and whole blood. *P. falciparum* positive samples (by microscopic review and RDTs method). FTA Cards contain chemicals that lyses (removes) blood cells, denature proteins and protect nucleic acids from nucleases, oxidation and UV damage. Captured nucleic acid is ready for downstream applications in less than 30 min and is stable for years at room temperature. DNA was eluted according to manufacturer's instructions (Whatman). While from whole blood, 200 μl of sample was used for DNA extraction with the QIA amp midi kit, as described by the manufacturer (Qiagen). Extracted DNA was analyzed by using 1 % agarose gel.

Amplification of *pfcrt* Gene Fragment
--------------------------------------

Two-step nested PCR was done to amplify *pfcrt* gene fragment of 145 base pairs**.** Primers were designed, using DNA sequence of *P. falciparum* chloroquine resistant strain Dd2/Indochina (by Pub Med accession number AF030694). The sequences of primers used in round 1 and round 2 are given in [Table 1](#T1){ref-type="table"}.

###### 

Primers used for amplification of *pfcrt* gene fragment of 145 base pairs

  **PCR Round**               **Primer**                       **Primer Sequence (5′--3′)**   **Tm**
  --------------------------- -------------------------------- ------------------------------ ----------
  **1^st^ Round**             Crtd-A (forward primer)          5′-GGTGGAGGTTCTTGTCTTGGTA-3′   57.5 °C
  Crtd-B (reverse primer)     5′-GACCTATGAAGGCCAAAATGACTG-3′   56.7 °C                        
  **2^nd^ Round**             Crtd-C (forward primer)          5′-TGTGCTCATGTGTTTAAACTT-3′    50.06 °C
  Crtd --D (reverse primer)   5′-CAAAACTATAGTTACCAATTTT-3′     46.10 °C                       

Preparation of PCR Reaction Mix for Round 1 (*pfcrt*)
-----------------------------------------------------

The PCR mixture contained 1X PCR buffer (Promega), 2.0 mM MgCl~2~ (Promega), 0.2 mM dNTPs, 0.25 μM each primer, 1.25 units, 0.5 units Taq polymerase (Promega) and 5 μl template DNA. The total reaction volume was 50 μl.

Cycling conditions for PCR were: one cycle of 95 °C for 5 minutes followed by 30 cycles of 95 °C for 10 seconds, 57 °C for 30 seconds and 72 °C for 30 seconds, followed by a final extension at 72 °C for 10 minutes.

PCR Reaction Mix Preparation for Round 2 (*pfcrt*)
--------------------------------------------------

The PCR mixture contained 1X PCR buffer (Promega), 2.0mM MgCl~2~ (Promega), 0.2 mM dNTPs, 0.25 μM each primer, 0.5 units Taq polymerase (Promega) and 5 μl template DNA. The total reaction volume was 50 μl.

Cycling conditions for PCR were: one cycle of 95 °C for 5 minutes followed by 35 cycles of 95 °C for 30 seconds, 48 °C for 30 seconds and 65 °C for 30 seconds, followed by a final extension at 65 °C for 3 minutes.

Amplified PCR products of each gene fragment were electrophoresed using 3 % agarose gel and visualized on UV. PCR products were cleaned using Exonuclease I (BioLabs Inc) and sequenced in both directions using Big Dye® Terminator system.

Statistical Analysis
--------------------

Results of sequencing were analyzed by the programme of Applied Bio-system (sequence scanner V, 0.1).

Results
=======

Sampling was carried out in Muzaffargarh, Pakistan from November 2008 to November 2010 (25 Months), in order to find out the malaria frequency. During this period, 10372 blood films of suspected malarial patients were prepared and examined. Their positivity rates for the infection of *Plasmodium* (both *falciparum* and *vivax*), *P. vivax* and *P. falciparum* were 2220, 2009 and 211 respectively. In this duration, slide positivity rate (SPR), *P. vivax* positivity rate % (VPR) and *P. falciparum* positivity rate (FPR) were 21.40 %, 19.37 % and 2.03 % respectively. The difference in *P. vivax* (90.49%) and *P. falciparum* (9.51%) infection was found highly significant (χ^2^= 1456, P\< 0.001).

Extracted DNA
-------------

Samples positive for *P. falciparum* (211) were used for DNA extraction. Genomic DNA is shown in [Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}.

![Gel electrophoresis picture showing extracted genomic DNA of falciparum positive malarial patients (Lane L shows 100bp ladder, lane 1--7 show genomic DNA)](JAD-9-204-g002){#F2}

![Gel electrophoresis picture showing amplified *pfcrt* gene fragment (145bp) (by using DNA extracted from the whole blood). Lane 1 and 2 show negative and positive controls respectively, lanes 3 to 12 show patient samples, lane 13 shows 100bp DNA Marker](JAD-9-204-g003){#F3}

Amplification of *pfcrt* (codon 72--76)
---------------------------------------

All the 211 *P. falciparum* positive samples were amplified using polymerase chain reaction. Amplification was carried out of the extracted DNA from whole blood and from FTA blood spotted cards.

*pfcrt* (codon 72--76) Amplification (by using disc of blood spotted FTA cards)
-------------------------------------------------------------------------------

Amplification by using the disc (2mm) was also conducted by using punched disc from FTA blood spotted cards. Product of (145bp) was visible as show in [Fig. 4](#F4){ref-type="fig"}.

![Picture of gel electrophoresis showing amplified *pfcrt* gene fragment (145bp) (by using disc of blood spotted card). Lane 1 and 2 show negative and positive controls respectively, lanes 3 to 12 show patient samples, lane 13 shows 100bp DNA Marker](JAD-9-204-g004){#F4}

Similar PCR results were obtained using DNA extracted from whole blood and FTA blood spotted cards which showed that FTA cards were found equally efficient for storage of blood for PCR reaction.

Sequencing Result
-----------------

Sequencing results were analyzed by using Applied-Biosystem VI software. It showed only one type of haplotype sequence S~agt~ VMNT (AGTGTAATGAATACA)from codon 72--76 in all samples. No wild type CVMNT or other drug resistant (mutant) haplotype was found. [Fig. 5](#F5){ref-type="fig"} is depicting sequencing results of *pfcrt* (codon 72--76) with forward primer.

![Sequencing results of *pfcrt* (codon 72--76)](JAD-9-204-g005){#F5}

Discussion
==========

Present findings showed that overall SPR observed in Muzaffargarh, Pakistan was 21.40 %. According to the report of Ministry of Health, (2006) malaria was the second most prevalent disease in Pakistan ([@B32]). Akin figures of SPR (19.7% and 19.40%) were reported from Punjab and Khyber Pakhtunkhwa ([@B16], Mohammad et al. 2010), which were respectively 1.64 % and 2.00 % less than present study. SPR reported from India has shown the percentages of 25.2 % and 24.54 % ([@B9], Panigahi et al. 2011), which were 3.80% and 3.14% higher than in current study.

Although malaria is rife worldwide but the maximum numbers of devastations caused by it are in Sub-Saharan Africa ([@B57]). In Africa 30.20 %, 27.07 % and 22.60 % SPR was reported from Uganda, Ethiopia and Tanzania ([@B19], [@B59], [@B30]) and these figures indicated an enhancement of 8.80 %, 5.67 % and 1.20 % respectively than the figures of the current study. These differences may be due to geographical, climatic, economic and cultural variations.

In the current study, *P. vivax*, was the predominant specie of this region. The overall infection caused by *P. vivax* and *P. falciparum* was 90.49 % and 9.51 % respectively, and the difference between the infection of *P. vivax* and *P. falciparum* was highly significant (χ^2^= 1456, P\< 0.001). Similar figures were collected from Muzaffarabad, Azad Kashmir and Khyber Pakhtunkhwa, occurrence of *P. vivax* infection (90.40% 92.20%, 92.20%) was far more than that caused by *P. falciparum* infection (9.6%, 7.8% and 7.8%) ([@B18], Jamal et al. 2005, [@B17]). Similarly higher incidence of *P. vivax* infection (72.4%) than *P. falciparum* infection (24.1%) was reported from Baluchistan province ([@B16]). Some other figures from the same province showed higher incidence of *P. vivax* infection (58.9%, 51.8%, 88.6%, 72.3%) than *P. falciparum* infection (41%, 48.1%, 11.3%, 27.6%) ([@B58]). Infections caused by *P. vivax* were also reported more than those of *P. falciparum* from some areas of Sind ([@B24], [@B3]). *P. vivax* infection (11.70%, 75%) was less than *P. falciparum* infection (88.29%, 85%) in some areas or Indian ([@B9], [@B33]). Similarly, *P. falciparum* (90%, 70%, 90.7% 68.53%) was predominant specie in some African regions ([@B37], [@B59], [@B22]).

Currently, parasites strains are exhibiting resistance to all major classes of drug present in the field and some of them have been withdrawn from use because of their ineffectiveness. Unfortunately we are unaware that where the next generation of antimalarial will come from ([@B13]). Core objective of the study was the scrutiny of mutant and wild types of *pfcrt* (codon 72--76). *pfcrt* gene fragment of 145bp was amplified in all positive *P. falciparum* (211) samples. Results showed 100 % S~agt~ VMNT (ser-val-meth-asn-thr). No S~tct~VMNT haplotype or wild type (CVMNK) was observed. Origin of S~agt~VMNT had been hypothesized from Mato Grasso, Brazil ([@B50]) and was reported from Guyana, Peru, Suriname, Venezuela ([@B7], [@B8], [@B34], [@B28], [@B12]). Clinical resistance to chloroquine (CQ) and amodiaquine (AQ) was found associated with mutations in *pfcrt* gene ([@B36], [@B4]). [@B43] correlated high level resistance to AQ metabolite desethylamodiaquine (DEAQ) in tests (*in vitro*) with the presence of SVMNT haplotype of *pfcrt*. [@B28], [@B60], and [@B4] detected high prevalence of this haplotype in the parasitic population of Brazil, Papua New Guinea, Laos, Afghanistan and Iran. Esmaeili et al. (2008) also reported very high prevalence of K76T mutation in an endemic district of Iran. These results were also supported by the study carried out (in vitro) on natural *P. falciparum* isolate, laboratory reference strain, parasites transfected with allelic replacement and progeny of genetic crosses ([@B46], [@B43]). In the past, SVMNT (ser-val-meth-asn-thr) allele carrying parasites had been reported twice, in 1996--1997 from Africa and in 2004 from Tanzania ([@B1]). Three common haplotypes of *pfcrt* are CVMNK (CQS, present in all geographic regions), CVIET (CQR found in Africa and South East Asia), SVMNT (CQR, S~agt~ VMNT is present in some countries of Asia and S~tct~ VMNT is found in South America) ([@B55], [@B49]). In the area of Muzaffargarh *P. vivax* was predominant specie so CQ exposure was higher. It may be the main reason of high prevalence of spreading CQR parasite (having *pfcrt* "SVMNT") in this area. Similar findings were reported from India, mutant *pfcrt* "SVMNT" haplotype was endemic in those areas, where *P. vivax* was dominant specie ([@B25]).

Conclusion
==========

Prior to everything else, appropriate diagnosis of *Plasmodium* and its species is highly necessary. A treatment initiated without proper diagnosis not only increases the probabilities of drug resistance, but also invites complications. Malaria controlling policies should be decentralized: made and implemented at province and district levels. Proper understanding and careful evaluation of local epidemiological pattern and the other aspects of malaria can produce base-line data in planning task for devising control strategies. The drug resistance issue is likely to pose long term challenges for us. Hybrid of conventional and neo drugs can help to conserve the efficiency of valuable anti malarial medicines, but choosing the right combination partners will continue to require the study of presently known and emerging mechanism.

The results show high prevalence of CQ resistance and AQ resistant genes. Excessive presence of CQ and AQ resistant genes in plasmodium population isolated from the people of Muzaffargarh suggest establishing the base line for monitoring of mutations. This is evident now that in this area, CQ or AQ will not be effective for the victims of *P. falciparum* infection. AQ is not recommended to be used as a partner drug in ACT in this locality, so as to ward off future catastrophes.
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